Recent Progress in Clinical Development of Therapeutic Antibodies Targeting Glycan-Binding Proteins.

CONCLUSION: There are several therapeutic antibodies being developed targeting glycan-binding proteins, including CD22, CD33, DEC-205, and CD62P, for different diseases. The clinical investigations demonstrated benefits of treatments with one antibody-drug conjugate against CD22 being approved by the regulatory agencies. The recent progresses in clinical developments of these antibodies have provided great promises in therapeutic targeting of more glycan-binding proteins for treating multiple diseases, including inflammation, autoimmune diseases, and hematological malignancies. PMID: 29521224 [PubMed - as supplied by publisher]
Source: Current Drug Targets - Category: Drugs & Pharmacology Authors: Tags: Curr Drug Targets Source Type: research